Understanding the place for GLP‐1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Understanding the place for
GLP‐1RA
therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 23, Issue S3, Pages 40-52
Publisher
Wiley
Online
2021-09-14
DOI
10.1111/dom.14500
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Type-2 diabetes patients at high risk for cardiovascular events: time to challenge the ‘metformin-always first’ paradigm
- (2021) Victor Aboyans et al. European Journal of Preventive Cardiology
- Gaps in Evidence‐Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease
- (2021) Adam J. Nelson et al. Journal of the American Heart Association
- Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
- (2021) Alessandro Mantovani et al. Metabolites
- Heart Disease and Stroke Statistics—2021 Update: A Report From the American Heart Association
- (2021) Salim S. Virani et al. CIRCULATION
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prototype of an evidence‐based tool to aid individualized treatment for type 2 diabetes
- (2021) John B. Buse et al. DIABETES OBESITY & METABOLISM
- CARDIOLOGIST USE OF SGLT2 INHIBITORS AND GLP-1 RECEPTOR AGONISTS SINCE RELEASE OF FAVORABLE CARDIOVASCULAR OUTCOMES TRIALS: A NATIONAL STUDY
- (2021) Rishav Adhikari et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England
- (2021) Kamlesh Khunti et al. Lancet Diabetes & Endocrinology
- Application of 2021 American Diabetes Association Glycemic Treatment Clinical Practice Recommendations in Primary Care
- (2021) Caitlin Colling et al. DIABETES CARE
- Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
- (2021) Hertzel C. Gerstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- How glucagon-like peptide 1 receptor agonists work
- (2021) Christine Rode Andreasen et al. Endocrine Connections
- Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study
- (2020) Jakob S. Knudsen et al. PLoS One
- Sex Differences in Cardiovascular Effectiveness of Newer Glucose‐Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus
- (2020) Valeria Raparelli et al. Journal of the American Heart Association
- Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials
- (2020) Lisa Ludwig et al. Cardiovascular Diabetology
- Number needed to treat in cardiovascular outcome trials of glucagon‐like peptide‐1 receptor agonists: A systematic review with temporal analysis
- (2020) Melanie J. Davies et al. DIABETES OBESITY & METABOLISM
- 624-P: Primary Care Education Leads to Improved Diabetes Knowledge and Clinical Practice
- (2020) RYAN WOOLLEY et al. DIABETES
- Is Coronary Artery Disease Inevitable in Type 2 Diabetes? From a Glucocentric to a Holistic View on Patient Management
- (2020) Giulia Ferrannini et al. DIABETES CARE
- Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial
- (2020) Matthew J. Crowley et al. DIABETES CARE
- 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
- (2020) Sandeep R. Das et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update
- (2020) Lorraine Lipscombe et al. Canadian Journal of Diabetes
- Risk of Cardiovascular Outcomes in Type 2 Diabetes Patients Following Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-IRA Therapy
- (2020) Chintan V. Dave et al. CIRCULATION
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression
- (2020) M. Angelyn Bethel et al. DIABETES CARE
- Real‐world use of cardioprotective glucose‐lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019
- (2020) Kristian L. Funck et al. DIABETES OBESITY & METABOLISM
- Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
- (2020) Brent A McLean et al. ENDOCRINE REVIEWS
- Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin
- (2020) Giulia Ferrannini et al. EUROPEAN HEART JOURNAL
- Effect Of Metformin On All-Cause Mortality And Major Adverse Cardiovascular Events: An Updated Meta-Analysis Of Randomized Controlled Trials
- (2020) Matteo Monami et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Global survey investigating causes of treatment inertia in type 2 diabetes cardiorenal risk management
- (2020) Naresh Kanumilli et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis
- (2019) Lana C. Pinto et al. Scientific Reports
- Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of MajorAdverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
- (2019) Thomas A. Zelniker et al. CIRCULATION
- Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists
- (2019) Muthiah Vaduganathan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Use of Guideline-Recommended Risk-Reduction Strategies Among Patients with Diabetes and Atherosclerotic Cardiovascular Disease: Insights from Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD)
- (2019) Suzanne V. Arnold et al. CIRCULATION
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trends in Antidiabetic Utilization and Expenditure in Denmark: A 22‐Year Nationwide Study
- (2019) Camilla Bang et al. DIABETES OBESITY & METABOLISM
- WITHDRAWN: Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition
- (2019) Pouya Saeedi et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- Implications of Specialist Density for Diabetes Care in the United States
- (2019) Ravi B. Patel et al. JAMA Cardiology
- Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension
- (2019) Johanna Helmstädter et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETOLOGIA
- Comments on the 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases
- (2019) Anders Jorsal et al. EUROPEAN HEART JOURNAL
- MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
- (2019) Michael A Nauck et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- An overview of GLP-1 agonists and recent cardiovascular outcomes trials
- (2019) Kelsey H Sheahan et al. POSTGRADUATE MEDICAL JOURNAL
- Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
- (2019) Marco Castellana et al. Scientific Reports
- Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
- (2018) Charlotte Granhall et al. CLINICAL PHARMACOKINETICS
- Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
- (2018) Tina Vilsbøll et al. DIABETES OBESITY & METABOLISM
- Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
- (2018) Rodrigo Oliveira Moreira et al. Diabetology & Metabolic Syndrome
- Recent updates on GLP-1 agonists: Current advancements & challenges
- (2018) Dilip Sharma et al. BIOMEDICINE & PHARMACOTHERAPY
- New avenues in the regulation of gallbladder motility - implications for the use of glucagon-like peptide-derived drugs
- (2018) Ida M Gether et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?
- (2018) Guntram Schernthaner et al. Cardiovascular Diabetology
- Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes
- (2018) Charlotte Granhall et al. CLINICAL PHARMACOKINETICS
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
- (2018) DIABETES CARE
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
- (2017) Carel W le Roux et al. LANCET
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes
- (2017) Mary E. Herman et al. PROGRESS IN CARDIOVASCULAR DISEASES
- Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom
- (2017) Lei Qin et al. Diabetes Therapy
- Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom
- (2017) Lei Qin et al. Diabetes Therapy
- The Cardiovascular Biology of Glucagon-like Peptide-1
- (2016) Daniel J. Drucker Cell Metabolism
- Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial
- (2016) Julio Rosenstock et al. DIABETES CARE
- Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial
- (2016) J. Skov et al. DIABETES OBESITY & METABOLISM
- A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients
- (2016) Mirna S. Abd El Aziz et al. DIABETES OBESITY & METABOLISM
- Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials
- (2016) Karolin Bettge et al. DIABETES OBESITY & METABOLISM
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease
- (2016) Robert A. Scott et al. Science Translational Medicine
- Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials
- (2015) Jeanne S. Geiser et al. CLINICAL PHARMACOKINETICS
- Association of Cardiometabolic Multimorbidity With Mortality
- (2015) Emanuele Di Angelantonio et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)
- (2014) John B. Buse et al. DIABETES CARE
- Changes in Diabetes-Related Complications in the United States, 1990–2010
- (2014) Edward W. Gregg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes
- (2014) Stephen C L Gough et al. Lancet Diabetes & Endocrinology
- Prognostic Significance of Silent Myocardial Infarction in Newly Diagnosed Type 2 Diabetes Mellitus
- (2013) Timothy M.E. Davis et al. CIRCULATION
- Epidemiology of Diabetes and Diabetes Complications in the Elderly: An Emerging Public Health Burden
- (2013) Mark Corriere et al. Current Diabetes Reports
- Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis
- (2013) O. J. Phung et al. DIABETIC MEDICINE
- Exenatide Reduces Final Infarct Size in Patients With ST-Segment–Elevation Myocardial Infarction and Short-Duration of Ischemia
- (2012) Jacob Lønborg et al. Circulation-Cardiovascular Interventions
- Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study
- (2012) DIABETES CARE
- Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
- (2011) M. A. Nauck et al. DIABETES
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
- (2010) The Emerging Risk Factors Collaboration LANCET
- Relationship between glycated haemoglobin and microvascular complications: Is there a natural cut-off point for the diagnosis of diabetes?
- (2009) C. Sabanayagam et al. DIABETOLOGIA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started